John W. Walsh Alpha-1 Home Infusion Act of 2025 This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.
Have questions about this legislation?
Our AI can explain provisions, analyze impacts, and answer questions in plain English.
Already have an account? Sign in
Make your voice heard on this bill.
Upgrade to Plus to generate an AI letter and send it to your House representative.
Get an instant AI-powered breakdown of this bill — what it does, who it affects, and what matters.
Create free accountAlready have an account? Sign in
Hear what historical figures and modern thinkers might say about this legislation.
Founding Fathers
Historical Leaders
Modern Thinkers
See how Jefferson, Churchill, or Einstein would react to this bill.
Create free accountAlready have an account? Sign in